Dermaliq Therapeutics is a private, clinical-stage dermatology company based in Wilmington, Delaware, founded in 2021 as a spin-off of Novaliq GmbH, a German ophthalmology company. That parentage matters more than it might first appear. Novaliq developed a delivery platform built on semifluorinated alkanes, lipophilic carrier molecules that can dissolve and transport active ingredients without needing the preservatives, penetration enhancers, or aqueous emulsifiers that most topical formulations rely on. Novaliq used that platform, under the brand name EyeSol, to build two FDA-approved dry eye drugs, Miebo and Vevye. Dermaliq holds the patent rights to apply the same underlying chemistry to skin and hair follicles, marketed as hyliQ.

DLQ01 is hyliQ's first hair loss candidate: a topical solution built around a prostaglandin F2α analogue, applied twice daily to the balding scalp. The pitch is straightforward. Prostaglandin F2α analogues are already a validated class in dermatology, but earlier attempts to use them on the scalp struggled to get the active ingredient into the hair follicle in a useful concentration. Dermaliq's argument is that hyliQ can solve that delivery problem where earlier formulations struggled. Whether it does is an open question this article returns to, because the delivery platform itself has a strong track record in the eye, but DLQ01 is its first real test in skin.

Unlike most compounds on our pipeline coverage, DLQ01's mechanism did not originate in a hair loss lab. It traces back to an accidental observation in glaucoma patients using prostaglandin F2α eye drops, some of whom grew longer, thicker, darker eyelashes as a side effect. That observation led directly to bimatoprost (Latisse), which the FDA approved in 2008 for eyelash hypotrichosis and which remains, to this day, the only FDA-approved prostaglandin analogue for a hair-growth indication. The receptor involved, the prostaglandin F2α receptor (FP receptor), is expressed in the dermal papilla of anagen human scalp follicles and signals through a pathway that mobilises intracellular calcium, prolonging the growth (anagen) phase of the hair cycle and increasing follicle size. For background on what that phase transition means for hair count, see our guide to the hair growth cycle.

The gap is that despite this receptor-level rationale being known for over two decades, no prostaglandin-pathway drug has ever been approved for scalp androgenetic alopecia specifically. A 2026 mechanistic review in Pharmacological Reports points to a plausible reason: for years, prostaglandin analogues circulated in a regulatory grey zone as ingredients in over-the-counter European eyelash and eyebrow serums, sold as cosmetics rather than drugs. That cosmetic route allowed prostaglandin analogues to circulate without the kind of formal drug-development programme that a scalp hair-loss treatment would require. Regulatory scrutiny has only tightened recently: the EU's Scientific Committee on Consumer Safety flagged safety concerns about cosmetic prostaglandin analogues in 2022, and in 2025 concluded that specific prostaglandin analogues cannot be considered safe in cosmetic products intended to promote eyelash or eyebrow growth. That regulatory history is a useful real-world illustration of the line our own cosmetic-versus-medicine article covers: DLQ01, as an investigational drug candidate going through formal FDA trials, sits on the medicine side of that line, in contrast to the cosmetic serums the same drug class spent years circulating in.

One detail worth being direct about: Dermaliq has never publicly disclosed which specific prostaglandin F2α molecule DLQ01 contains. Every company statement describes it only as "a proprietary hyliQ technology-based topical prostaglandin (PG) F2α drug." Hair loss forums have speculated that it may be latanoprost, the same molecule behind Xalatan and, in its ester-prodrug form, one of the two prostaglandin analogues with the most published scalp data. That speculation is unconfirmed. AmpleLab has not found a company statement, patent filing, or trial registration that names the specific compound, and we are not asserting it is latanoprost. What can be said with confidence is that DLQ01 belongs to a drug class with real precedent in hair biology, delivered through a platform with real precedent in a different tissue, combined in a formulation whose exact chemical identity has not been made public.

The trial (NCT05636904, protocol DLQ01-001) was a randomised, triple-blind, vehicle- and comparator-controlled study conducted at Sinclair Dermatology in Melbourne, with Prof. Rodney Sinclair as principal investigator. It enrolled 120 men aged 18 to 60 with Norwood-Hamilton vertex grades IIIv through V, split evenly into four arms of 30: DLQ01 high dose, DLQ01 low dose, an active-ingredient-free vehicle, and 5% minoxidil solution as an active comparator. All four solutions were applied twice daily to the vertex balding area for six months, with endpoints including target area hair count (TAHC), the anagen-to-telogen hair ratio, and cutaneous safety.

This is a genuinely encouraging topline result for an early-stage hair loss drug, and the head-to-head design against an approved comparator (rather than just a vehicle) is a stronger evidentiary setup than most pipeline compounds ever get. It deserves to be read carefully rather than dismissed, and it also deserves the same scrutiny AmpleLab applies to every pipeline candidate we cover.

First, the trial had two separate DLQ01 dose arms, high and low, but the July 2024 press release reports a single "DLQ01 treatment" figure of 12.3% and a single 83% responder rate. It does not state whether that is a pooled result across both doses, the result from one specific dose, or an average, and it does not report the two doses separately. For a dose-ranging trial, that is a meaningful gap: a reader cannot currently tell whether the effective dose is the low one, the high one, or whether the two performed similarly.

Second, Dermaliq's own website separately advertises DLQ01's Phase 2 data as delivering a "500% relative hair count improvement" over vehicle, a very different-sounding number from the "12.3% from baseline" figure in the formal press release. These are not necessarily contradictory: if the vehicle arm's own hair count barely moved from baseline, a modest absolute treatment effect can produce a very large relative multiplier once it is expressed as a percentage of the vehicle's response rather than as a percentage of baseline. Both framings can be mathematically accurate and describe the same underlying result. But they are not interchangeable, and a marketing page choosing the more dramatic-sounding framing is a reason for a careful reader to ask for the absolute numbers, not a reason to distrust the trial outright.

Third, and most simply: as of this writing, more than two years after the July 2024 announcement, AmpleLab could not find any peer-reviewed publication of the DLQ01 Phase 1b/2a dataset. Everything reported about this trial's results, including the numbers above, comes from company press releases and company-authored conference material, not from an independently reviewed journal article. Dermaliq said in July 2024 that publication was planned "in the near future." That has not yet materialised in the public record. This does not mean the data is wrong. It means it has not yet passed the outside check that peer review is designed to provide, and any claim about DLQ01's efficacy, including the ones in this article, should be understood as resting on the company's own reporting until that changes.

DLQ01 is not the only attempt to test a prostaglandin F2α analogue on the scalp, and the independently published attempts give useful, if more modest, context. A small 2012 pilot from Berlin (Blume-Peytavi et al., Journal of the American Academy of Dermatology) randomised 16 men to topical latanoprost 0.1% or placebo, once daily for 24 weeks, and found a statistically significant increase in both terminal and vellus hair density versus baseline and versus the placebo-treated area. It was small and never followed up with a larger trial, but it was independently conducted and peer-reviewed.

Set side by side, the picture is coherent rather than contradictory. Two small, independently peer-reviewed pilot studies support the basic premise that prostaglandin F2α pathway activation can measurably affect scalp hair, at a modest scale, with no major safety signal reported in these small studies. DLQ01's reported effect size is numerically larger than the result reported for minoxidil in that trial, and its N=120, six-month, comparator-controlled design is considerably larger and better-controlled than either independent pilot above. What it is missing, so far, is the independent peer review that both smaller studies already have.

Dermaliq closed a $15 million Series A round in January 2022, split across three dermatology programmes: DLQ01 for hair loss, DLQ02 (a topical calcineurin inhibitor for plaque psoriasis), and a third indication. Investors included 3E Bioventures Capital, the Chinese pharmaceutical group Double Whale Pharmaceutical (also referred to as Beijing Whale Technology Corporation), and Novaliq itself. That round funded the Phase 1b/2a trial covered above, but by February 2025, when Dermaliq announced the addition of hair follicle biologist Ralf Paus to its scientific advisory board, the company stated it was "actively seeking strategic partners and investors" for a Series B round specifically to fund DLQ01's Phase 2b development. As of Dermaliq's own exhibitor listing for the BIO International Convention in June 2026, the company was still describing its lead asset by reference to "a recent Phase 2a trial," with no public announcement of a funded Phase 2b or Phase 3 programme. Taken together, that is close to two years between a strong topline readout and any confirmed next clinical step, a gap that coincides with the company's continued search for funding for the next phase, although Dermaliq has not publicly attributed the delay to funding.

Dermaliq is a small operation, listed at around nine to ten employees, and it has spent the funding gap diversifying rather than standing still. In May 2025 it announced a non-exclusive collaboration with DEBRA Research, a nonprofit focused on epidermolysis bullosa, to adapt hyliQ for touchless wound-care and anti-itch delivery in that unrelated, fragile-skin condition. What that diversification means for the future of DLQ01 isn't clear from the public record.

This article is provided for educational purposes and does not constitute medical or investment advice. DLQ01 is an investigational compound not approved for any use by the FDA, MHRA, or any other regulatory body. AmpleLab products are unrelated to DLQ01 and are not intended to diagnose, treat, cure, or prevent any condition.

AmpleLab.